The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients

Using quantitative reverse-transcription polymerase chain reaction we investigated the significance of achieving molecular complete remission (CR) in 12 patients with bcr/abl-positive acute lymphocytic leukemia treated with imatinib. The 6 patients who achieved molecular CR had significantly better...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haematologica (Roma) 2004-10, Vol.89 (10), p.1269-1271
Hauptverfasser:	Piccaluga, PP, Malagola, M, Amabile, M, Rondoni, M, Paolini, S, Pane, F, Russo, D, Visani, G, Baccarani, M, Martinelli, G
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Benzamides Biomarkers, Tumor - blood Disease-Free Survival Drug Evaluation Fusion Proteins, bcr-abl - blood Humans Imatinib Mesylate Life Tables Neoplasm Proteins - blood Piperazines - therapeutic use Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality Pyrimidines - therapeutic use Remission Induction Survival Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Using quantitative reverse-transcription polymerase chain reaction we investigated the significance of achieving molecular complete remission (CR) in 12 patients with bcr/abl-positive acute lymphocytic leukemia treated with imatinib. The 6 patients who achieved molecular CR had significantly better relapse-free survival (RFS) than the others (9 vs 4 months) (p=0.000). Moreover, the 6 patients with a bcr-abl/GAPDHx100,000 ratio
ISSN:	0390-6078 1592-8721